Cargando…

HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China

BACKGROUND: Transmitted drug resistance (TDR) is an important public health issue, because TDR-associated mutation may affect the outcome of antiretroviral treatment potentially or directly. Men who have sex with men (MSM) constitute a major risk group for HIV transmission. However, current reports...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Yang, Li, Shuming, Li, Zhenpeng, Zhang, Zheng, Zhao, Jianhong, Li, Li, Wang, Lijuan, Yin, Qianqian, Wang, Yan, Zeng, Zhaoli, Shao, Yiming, Ma, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271504/
https://www.ncbi.nlm.nih.gov/pubmed/25510523
http://dx.doi.org/10.1186/s12879-014-0689-7
_version_ 1782349618598641664
author Jiao, Yang
Li, Shuming
Li, Zhenpeng
Zhang, Zheng
Zhao, Jianhong
Li, Li
Wang, Lijuan
Yin, Qianqian
Wang, Yan
Zeng, Zhaoli
Shao, Yiming
Ma, Liying
author_facet Jiao, Yang
Li, Shuming
Li, Zhenpeng
Zhang, Zheng
Zhao, Jianhong
Li, Li
Wang, Lijuan
Yin, Qianqian
Wang, Yan
Zeng, Zhaoli
Shao, Yiming
Ma, Liying
author_sort Jiao, Yang
collection PubMed
description BACKGROUND: Transmitted drug resistance (TDR) is an important public health issue, because TDR-associated mutation may affect the outcome of antiretroviral treatment potentially or directly. Men who have sex with men (MSM) constitute a major risk group for HIV transmission. However, current reports are scarce on HIV TDR-associated mutations and their co-variation among MSM. METHODS: Blood samples from 262 newly diagnosed HIV-positive, antiretroviral therapy (ART)-naïve MSM, were collected from January 2011 and December 2013 in Beijing. The polymerase viral genes were sequenced to explore TDR-associated mutations and mutation co-variation. RESULTS: A total of 223 samples were sequenced and analyzed. Among them, HIV-1 CRF01_AE are accounted for 60.5%, followed by CRF07_BC (27.8%), subtype B (9.9%), and others. Fifty-seven samples had at least one TDR-associated mutation, mainly including L10I/V (6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I (2.7%), with different distributions of TDR-associated mutations by different HIV-1 subtypes and by each year. Moreover, eight significant co-variation pairs were found between TDR-associated mutations (V179D/E) and seven overlapping polymorphisms in subtype CRF01_AE. CONCLUSIONS: To date, this work consists the most comprehensive genetic characterization of HIV-1 TDR-associated mutations prevalent among MSM. It provides important information for understanding TDR and viral evolution among Chinese MSM, a population currently at particularly high risk of HIV transmission. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0689-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4271504
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42715042014-12-20 HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China Jiao, Yang Li, Shuming Li, Zhenpeng Zhang, Zheng Zhao, Jianhong Li, Li Wang, Lijuan Yin, Qianqian Wang, Yan Zeng, Zhaoli Shao, Yiming Ma, Liying BMC Infect Dis Research Article BACKGROUND: Transmitted drug resistance (TDR) is an important public health issue, because TDR-associated mutation may affect the outcome of antiretroviral treatment potentially or directly. Men who have sex with men (MSM) constitute a major risk group for HIV transmission. However, current reports are scarce on HIV TDR-associated mutations and their co-variation among MSM. METHODS: Blood samples from 262 newly diagnosed HIV-positive, antiretroviral therapy (ART)-naïve MSM, were collected from January 2011 and December 2013 in Beijing. The polymerase viral genes were sequenced to explore TDR-associated mutations and mutation co-variation. RESULTS: A total of 223 samples were sequenced and analyzed. Among them, HIV-1 CRF01_AE are accounted for 60.5%, followed by CRF07_BC (27.8%), subtype B (9.9%), and others. Fifty-seven samples had at least one TDR-associated mutation, mainly including L10I/V (6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I (2.7%), with different distributions of TDR-associated mutations by different HIV-1 subtypes and by each year. Moreover, eight significant co-variation pairs were found between TDR-associated mutations (V179D/E) and seven overlapping polymorphisms in subtype CRF01_AE. CONCLUSIONS: To date, this work consists the most comprehensive genetic characterization of HIV-1 TDR-associated mutations prevalent among MSM. It provides important information for understanding TDR and viral evolution among Chinese MSM, a population currently at particularly high risk of HIV transmission. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0689-7) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-16 /pmc/articles/PMC4271504/ /pubmed/25510523 http://dx.doi.org/10.1186/s12879-014-0689-7 Text en © Jiao et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jiao, Yang
Li, Shuming
Li, Zhenpeng
Zhang, Zheng
Zhao, Jianhong
Li, Li
Wang, Lijuan
Yin, Qianqian
Wang, Yan
Zeng, Zhaoli
Shao, Yiming
Ma, Liying
HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China
title HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China
title_full HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China
title_fullStr HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China
title_full_unstemmed HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China
title_short HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China
title_sort hiv-1 transmitted drug resistance-associated mutations and mutation co-variation in hiv-1 treatment-naïve msm from 2011 to 2013 in beijing, china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271504/
https://www.ncbi.nlm.nih.gov/pubmed/25510523
http://dx.doi.org/10.1186/s12879-014-0689-7
work_keys_str_mv AT jiaoyang hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT lishuming hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT lizhenpeng hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT zhangzheng hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT zhaojianhong hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT lili hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT wanglijuan hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT yinqianqian hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT wangyan hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT zengzhaoli hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT shaoyiming hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina
AT maliying hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina